Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$3.51 USD
+0.10 (2.93%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.52 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRME 3.51 +0.10(2.93%)
Will PRME be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRME
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
Other News for PRME
Prime Medicine granted orphan status for glycogen storage disease
Wall Street Analysts Are Bullish on Top Healthcare Picks
Prime Medicine (PRME) Partners with Bristol Myers Squibb for Advanced T-Cell Therapies
Prime Medicine’s Strategic Alliances and Growth Potential Affirm Buy Rating
Buy Rating Affirmed for Prime Medicine on Strategic Partnerships and Technology Platform Potential